Introduction
Lung cancer
Non-small cell lung cancer (NSCLC)
Durvalumab as consolidation therapy after chemoradiation therapy for unresectable stage III NSCLC
Neoadjuvant ICI-based therapy for resectable NSCLC
Adjuvant atezolizumab therapy for stage IIB-III NSCLC with PD-L1 ≥ 1%
Organ system | Clinical trial | Cancer type | Phase | Participant numbers | Trial design | Estimated study completion (year) | Primary endpoint(s) |
---|---|---|---|---|---|---|---|
Lung | NCT02998528 (CheckMate 816) | Early Stage NSCLC | III | 350 | Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy VS Platinum Doublet Chemotherapy | 2028 | Event-Free Survival (EFS); Pathological Complete Response (pCR) |
NCT03456063 (IMpower030) | Resectable Stage II, IIIA, or Select IIIB NSCLC | III | 453 | Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy | 2026 | Event Free Survival | |
NCT04025879 (CA209-77 T) | Surgically Removable Early Stage NSCLC | III | 452 | Neoadjuvant Chemotherapy Plus Nivolumab VS Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo | 2024 | Event-Free Survival | |
NCT03425643 (KEYNOTE-671) | Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) NSCLC | III | 786 | Platinum Doublet Chemotherapy ± Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy | 2026 | Event Free Survival; Overall Survival | |
NCT03800134 (AEGEAN) | Resectable Stages II and III NSCLC | III | 800 | Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients | 2024 | Event-Free Survival; Pathological Complete Response | |
NCT05157776 | Resectable Locally Advanced NSCLC Harboring no Driver Mutations | III | 72 | Neoadjuvant Sintilimab and Platinum-based Chemotherapy | 2023 | Pathologically complete response rate | |
GI tract | NCT04807673 | Esophageal Squamous Cell Carcinoma | III | 342 | Pembrolizumab Plus Paclitaxel and Cisplatin VS Neoadjuvant Chemoradiotherapy Followed by Surgery | 2028 | Event Free Survival |
NCT04848753 | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | III | 500 | Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy | 2026 | Event Free Survival | |
NCT04973306 | Esophageal Squamous Cell Carcinoma | II-III | 176 | Anti-PD-1 antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy VS neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy | 2027 | Major pathologic response; OS | |
NCT04304209 | Colorectal Cancer | II-III | 195 | Neoadjuvant Sintilimab ± Chemoradiotherapy | 2026 | Pathologic complete response rate | |
NCT02743494 (CheckMate 577) | Resected stage II-III esophageal or GE junction cancer | III | 794 | Neoadjuvant chemoRT followed by complete resection, with residual disease adjuvant Nivolumab VS placebo | 2025 | Disease Free Survival | |
NCT05270824 | Advance Gastric Adenocarcinoma | III | 120 | Radical surgery after neoadjuvant immunotherapy (albumin Paclitaxel + Seggio + PD-1 inhibitor) VS adical surgery after neoadjuvant chemotherapy (albumin Paclitaxel + Seggio) | 2027 | CD8 + tumor-infiltrating lymphocytes in tumor tissue | |
NCT04882241 | Gastric Cancer | III | 120 | Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) VS Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment | 2025 | Event-Free Survival (EFS); Pathological Complete Response (pCR);Overall Survival | |
GU | NCT03732677 | Muscle Invasive Bladder Cancer | III | 988 | Durvalumab in Combination With Gemcitabine + Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone | 2026 | Event-Free Survival; Pathological Complete Response |
NCT04700124 | Muscle Invasive Bladder Cancer | III | 784 | Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) VS Neoadjuvant Gemcitabine and Cisplatin | 2026 | Event-Free Survival; Pathological Complete Response | |
NCT04209114 | Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible | III | 540 | Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, VS Nivolumab Alone Versus Standard of Care | 2024 | Event-Free Survival; Pathological Complete Response | |
NCT04209114 | MIBC ineligible for cisplatin | III | 540 | Neoadjuvant and Adjuvant Nivolumab + Bempeg/NKTR-214, VS Nivolumab Alone vs Standard of Care w radical cystectomy | 2024 | Event-Free Survival; Pathological Complete Response | |
NCT04700124 (KEYNOTE-B15) | Cisplatin-eligible Muscle Invasive Bladder Cancer | III | 784 | Perioperative Enfortumab Vedotin + Pembrolizumab 1 yr VS Neoadjuvant Gemcitabine and Cisplatin | 2026 | Event-Free Survival; Pathological Complete Response | |
GYN | NCT03038100 | Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | III | 1301 | Paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab VS paclitaxel, carboplatin and placebo | 2023 | PFS, OS |
Head and Neck | NCT03700905 | Head and Neck Cancer | III | 276 | Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy VS Standard Follow-up | 2024 | Disease Free Survival |
NCT03765918 (Keynote 689) | Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma | III | 704 | Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy | 2026 | Major Pathological Response (mPR);Event-free Survival | |
NCT05125055 | Oral Squamous Cell Carcinoma | II-III | 80 | Neoadjuvant Toripalimab and Albumin Paclitaxel /Cisplatin VS Docetaxel/ Cisplatin/ 5-fluorouracil (TPF) on Pathological Response in Patients | 2025 | Major pathologic response | |
NCT04557020 | High-risk Nasopharyngeal Carcinoma | III | 200 | Toripalimab with neoadjuvant cis Platinum and gemcitabine VS Standard cis Platinum and gemcitabine | 2024 | PFS | |
Skin | NCT04949113 | Macroscopic Stage III Melanoma | III | 420 | Neoadjuvant Ipilimumab Plus Nivolumab VS Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma | 2027 | Event Free Survival |
NCT04949113 (NADINA) | Stage III Melanoma | III | 420 | Neoadjuvant Ipilimumab + Nivolumab (adjuvant Nivo in residual disease or dabrafenib/tremetinib in BRAF V600 mut) VS Standard Adjuvant Nivolumab 1 yr | 2027 | Event Free Survival | |
Breast | NCT03725059 (KEYNOTE-756) | Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER + /HER2-) Breast Cancer | III | 1240 | Pembrolizumab VS Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy | 2031 | Event-Free Survival; Pathological Complete Response |
NCT03036488 | Triple Negative Breast Neoplasms | III | 1174 | Pembrolizumab Plus Chemotherapy VS Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy | 2025 | Event-Free Survival; Pathological Complete Response | |
NCT04613674 | Triple Negative Breast Cancer | III | 581 | Camrelizumab Plus Chemotherapy VS Placebo Plus Chemotherapy as Neoadjuvant Therapy i | 2023 | Pathological complete response rate | |
NCT02620280 (NeoTRIPaPDL1) | TNBC | III | 278 | Neoadjuvant Atezolizumab or placebo with Carbo/abraxane, surgery followed by adjuvant chemotherapy | 2022 | Event Free Survival | |
NCT03726879 (IMpassion050) | Early Her2 + Breast Cancer | III | 454 | Neoadjuvant Atezolizumab or Placebo wtih Neoadjuvant ddAC Followed By THP, adjuvant Atezo 1 yr VS placebo with Her2 HP/TDM1 | 2023 | Pathological Complete Response | |
NCT03595592 (APTneo) | Her2 + breast cancer | III | 650 | Neoadjuvant chemotherapy VS Atezolizumab + AC-TCHP VS Atezolizumab + TCHP, surgery followed by adjuvant Atezo + HP | 2026 | Event Free Survival | |
NCT04109066 (Checkmate 7FL) | High-risk, ER + , HER2-Early Breast Cancer | III | 1200 | Nivolumab VS Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy | 2032 | Pathological Complete Response, Event Free Survival | |
NCT03281954 | TNBC | III | 1520 | Neoadjuvant Chemotherapy With Atezolizumab or Placebo Followed by Adjuvant Atezolizumab or Placebo | 2024 | Pathological Complete Response, Event Free Survival |
Small cell lung cancer (SCLC)
Breast cancer
Genitourinary cancers
Bladder cancer
Non-muscle-invasive bladder cancer (NMIBC)
Locally advanced muscle-invasive bladder cancer
Kidney cancer
Trials | CheckMate 214 Nivolumab + Ipilimumab IV q3w X 4 then q4W | Keynote 426 Pembrolizumab + Axitinib 5–10 mg po bid | Javelin 101 Avelumab + Axitinib | CheckMate 9ER Nivolumab + Cabozantinib 40 mg po qd | CLEAR Pembrolizumab + Lenvatinib 20 mg po qd |
---|---|---|---|---|---|
Number of Patients | 1096 | 861 | 886 | 651 | 1069 (3 arms) |
Primary endpoints | ORR, PFS and OS int/poor | OS and PFS | OS and PFS in PD-L1 + | PFS | PFS, OS and safety |
ORR% (vs sunitinib %)CR% (vs sunitinib %) | 42 (vs 27) CR: 9 (vs 1) | 59.3 (vs 35.7) CR: 5.8 (vs 1.9) | 51.4 (vs 25.5) CR: 4.4 (vs 2.1) | 56 (vs 27) CR: 8 (vs 5) | 71.0 (vs 53.3%) (Len + evero) vs 36.1% (sunitinib) 16.1% vs 9.8% vs 4.2% |
OS hazard ratio | 0.66 (0.53–0.82) | 0.53 (0.38–0.74) | 0.78 (0.55–1.08) | 0.60 (0.40–0.89) | 0.66 (0.49–0.88) |
PFS (months) vs sunitinib | 12.4 vs 12.3 HR: 0.98 (0.79–1.23) | 15.1 vs 11.1 HR: 0.69 (0.57–0.84) | 13.8 vs 8.0 HR: 0.69 (0.56–0.83) | 16.6 vs 8.3 HR: 0.51 (0.41–0.64) | 23.9 vs 14.7 vs 9.2 HR: 0.39 |
Grade 3 and 4 toxicity % (sunitinib %) | 46 (vs 63) | 62.9 (vs 58) | 71.2 (vs 71.5) | 61 (vs 51) | 82.4 vs 83.1 vs 71.8 |
Toxicity-induced discontinuation % (sunitinib %) | 22 (vs 12) | 10.7 (vs 13.9) | 7.6 (vs 13.4) | 37.2 (vs 14.4) | |
FDA approval | 04/16/2018 | 04/22/2019 | 05/14/2019 | 01/21/2021 | 08/11/2021 |